Literature DB >> 6382011

Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.

J N Cohn, T B Levine, M T Olivari, V Garberg, D Lura, G S Francis, A B Simon, T Rector.   

Abstract

Hemodynamics, plasma norepinephrine, and plasma renin activity were measured at supine rest in 106 patients (83 men and 23 women) with moderate to severe congestive heart failure. During follow-up lasting 1 to 62 months, 60 patients died (57 per cent); 47 per cent of the deaths were sudden, and 45 per cent were related to progressive heart failure. Statistically unrelated to the risk of mortality were cause of disease (60 patients had coronary disease, and 46 had cardiomyopathy), age (mean, 54.8 years), cardiac index (mean, 2.11 liters per minute per square meter of body-surface area), pulmonary wedge pressure (mean, 24.5 mm Hg), and mean arterial pressure (mean, 83.2 mm Hg). A multivariate analysis of the five significant univariate prognosticators--heart rate (mean, 84.4 beats per minute), plasma renin activity (mean, 15.4 ng per milliliter per hour), plasma norepinephrine (mean, 700 pg per milliliter), serum sodium (mean, 135.7 mmol per liter), and stroke-work index (mean, 21.0 g-meters per square meter)--found only plasma norepinephrine to be independently (P = 0.002) related to the subsequent risk of mortality. Norepinephrine was also higher in patients who died from progressive heart failure than in those who died suddenly. These data suggest that a single resting venous blood sample showing the plasma norepinephrine concentration provides a better guide to prognosis than other commonly measured indexes of cardiac performance.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6382011     DOI: 10.1056/NEJM198409273111303

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  560 in total

Review 1.  Rational use of inotropic therapy in heart failure.

Authors:  G M Felker; C M O'Connor
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

Review 2.  Heart Failure: Treatment strategies for heart failure: beta blockers andantiarrhythmics.

Authors:  A P Maggioni
Journal:  Heart       Date:  2001-01       Impact factor: 5.994

Review 3.  Pathophysiology of heart failure: a look at the future.

Authors:  R M Delgado; J T Willerson
Journal:  Tex Heart Inst J       Date:  1999

Review 4.  Report of the NASPE/NHLBI Round Table on Future Research Directions in Atrial Fibrillation. North American Society of Pacing and Electrophysiology.

Authors:  S Saskena; M J Domanski; E J Benjamin; A J Camm; M D Ezekowitz; B J Gersh; J Jalife; G V Naccarelli; R E Vlietstra; D G Wyse
Journal:  J Interv Card Electrophysiol       Date:  2001-09       Impact factor: 1.900

5.  Regulation of the Epstein-Barr virus C promoter by AUF1 and the cyclic AMP/protein kinase A signaling pathway.

Authors:  E M Fuentes-Pananá; R Peng; G Brewer; J Tan; P D Ling
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 6.  Cardiovascular gene therapy for myocardial infarction.

Authors:  Maria C Scimia; Anna M Gumpert; Walter J Koch
Journal:  Expert Opin Biol Ther       Date:  2013-12-16       Impact factor: 4.388

7.  Changing mortality in dilated cardiomyopathy. The Heart Muscle Disease Study Group.

Authors:  A Di Lenarda; G Secoli; A Perkan; D Gregori; G Lardieri; B Pinamonti; G Sinagra; M Zecchin; F Camerini
Journal:  Br Heart J       Date:  1994-12

Review 8.  Neurohormonal mechanisms and the role of angiotensin-converting enzyme (ACE) inhibitors in heart failure.

Authors:  A J Coats; S Adamopoulos
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

9.  Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload.

Authors:  Timothy D O'Connell; Philip M Swigart; M C Rodrigo; Shinji Ishizaka; Shuji Joho; Lynne Turnbull; Laurence H Tecott; Anthony J Baker; Elyse Foster; William Grossman; Paul C Simpson
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

10.  Extension of myocardial necrosis differently affects MIBG retention in heart failure caused by ischaemic heart disease or by dilated cardiomyopathy.

Authors:  Cecilia Marini; Assuero Giorgetti; Alessia Gimelli; Annette Kusch; Nadia Sereni; Antonio L'abbate; Paolo Marzullo; Gianmario Sambuceti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.